3 results on '"Brittany Banbury"'
Search Results
2. Engaging Multistakeholder Perspectives to Identify <scp>Patient‐Centered</scp> Research Priorities Regarding Vaccine Uptake Among Adults With Autoimmune Conditions
- Author
-
Shilpa Venkatachalam, Kelly Gavigan, Laura Stradford, Vandana Dronadula, Angela Degrassi, W. Benjamin Nowell, Shubhasree Banerjee, Peter A. Merkel, Michael D. George, Jennifer Gordon, Dianne G. Shaw, Kalen Larsen, Lisa Emrich, Robert N. McBurney, Hope Sullivan, Ashira Blazer, Brittany Banbury, Kimberly N. Weaver, Michael D. Kappelman, and Jeffrey R. Curtis
- Subjects
Rheumatology - Abstract
Objective: The study objective was to prioritize topics for future patient-centered research to increase uptake of common vaccines, such as for pneumococcal pneumonia, influenza, herpes zoster, human papillomavirus, and severe acute respiratory syndrome coronavirus 2, among adults living with autoimmune conditions. Methods: A steering committee (SC) was formed that included clinicians, patients, patient advocates, and researchers associated with rheumatic diseases (psoriatic arthritis, rheumatoid arthritis, vasculitis), inflammatory bowel disease, and multiple sclerosis. Through a scoping review and discussions, SC members identified research topics regarding vaccine uptake and/or hesitancy for prioritization. A larger multistakeholder alliance that included patients and patient advocates, clinicians, researchers, policy makers, regulators, and vaccine manufacturers conducted a modified Delphi exercise online with three rating rounds and one ranking round. Frequency analysis and comparisons across stakeholder groups were conducted. A weighted ranking score was generated for each item in the ranking round for final prioritization. Results: Through the Delphi process, 33 research topics were identified, of which 13 topics were rated as critical by more than 70% of all stakeholders (n = 31). The two highest ranked critical topics per the full stakeholder group were “How well a vaccine works for adults with autoimmune conditions” and “How beliefs about vaccine safety affect vaccine uptake.”. Conclusion: A multistakeholder group identified key topics as critically important priorities for future research to decrease vaccine hesitancy and improve uptake of vaccines for adults with autoimmune conditions.
- Published
- 2023
3. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination
- Author
-
Brittany Banbury, Ramin S. Herati, Mala Masson, Amber Cornelius, Mimi Y. Kim, Rebecca H. Haberman, Mayce Haj-Ali, Mark J. Mulligan, Paula Rackoff, Kristina K Deonaraine, Jose U. Scher, Robert R. Clancy, Ashira D Blazer, Sara Stream, Amit Saxena, Alexis J Engel, Jill P. Buyon, Rebecca B Blank, Marie I. Samanovic, Peter M. Izmirly, Ghadeer Hasan, Chung-E Tseng, H. Michael Belmont, Allison Guttmann, Xianhong Xie, Benjamin Plotz, Sharon Ohana, Ruth Fernandez-Ruiz, and Gary Ho
- Subjects
Male ,Enzyme-Linked Immunospot Assay ,medicine.medical_treatment ,Full Length ,Antibodies, Viral ,Cohort Studies ,Immunogenicity, Vaccine ,systemic lupus erythematosus ,Prednisone ,immunosuppressants ,Immunology and Allergy ,Lupus Erythematosus, Systemic ,skin and connective tissue diseases ,B-Lymphocytes ,biology ,ELISPOT ,Immunosuppression ,Middle Aged ,Symptom Flare Up ,Vaccination ,seroreactivity ,Antirheumatic Agents ,Cohort ,Spike Glycoprotein, Coronavirus ,Female ,Antibody ,Immunosuppressive Agents ,medicine.drug ,2019-nCoV Vaccine mRNA-1273 ,Adult ,COVID-19 Vaccines ,Immunology ,Immunocompromised Host ,Interferon-gamma ,Immune system ,Rheumatology ,Neutralization Tests ,COVID‐19 ,medicine ,Humans ,Glucocorticoids ,BNT162 Vaccine ,Ad26COVS1 ,business.industry ,SARS-CoV-2 ,COVID-19 ,vaccination ,Regimen ,Case-Control Studies ,Immunoglobulin G ,biology.protein ,business - Abstract
To evaluate seroreactivity and disease flares after COVID-19 vaccination in a multiethnic/multiracial cohort of patients with systemic lupus erythematosus (SLE).Ninety SLE patients and 20 healthy controls receiving a complete COVID-19 vaccine regimen were included. IgG seroreactivity to the SARS-CoV-2 spike receptor-binding domain (RBD) and SARS-CoV-2 microneutralization were used to evaluate B cell responses; interferon-γ (IFNγ) production was measured by enzyme-linked immunospot (ELISpot) assay in order to assess T cell responses. Disease activity was measured by the hybrid SLE Disease Activity Index (SLEDAI), and flares were identified according to the Safety of Estrogens in Lupus Erythematosus National Assessment-SLEDAI flare index.Overall, fully vaccinated SLE patients produced significantly lower IgG antibodies against SARS-CoV-2 spike RBD compared to fully vaccinated controls. Twenty-six SLE patients (28.8%) generated an IgG response below that of the lowest control (100 units/ml). In logistic regression analyses, the use of any immunosuppressant or prednisone and a normal anti-double-stranded DNA antibody level prior to vaccination were associated with decreased vaccine responses. IgG seroreactivity to the SARS-CoV-2 spike RBD strongly correlated with the SARS-CoV-2 microneutralization titers and correlated with antigen-specific IFNγ production determined by ELISpot. In a subset of patients with poor antibody responses, IFNγ production was similarly diminished. Pre- and postvaccination SLEDAI scores were similar in both groups. Postvaccination flares occurred in 11.4% of patients; 1.3% of these were severe.In a multiethnic/multiracial study of SLE patients, 29% had a low response to the COVID-19 vaccine which was associated with receiving immunosuppressive therapy. Reassuringly, severe disease flares were rare. While minimal protective levels remain unknown, these data suggest that protocol development is needed to assess the efficacy of booster vaccination.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.